A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates

Journal of Experimental Medicine

Volumn 208, Issue 11, 2011, Pages 2217-2223

  Kari, Laszlo ^a   Whitmire, William M ^a   Olivares Zavaleta, Norma ^a   Goheen, Morgan M ^a   Taylor, Lacey D ^a   Carlson, John H ^a   Sturdevant, Gail L ^a   Lu, Chunxue ^a   Bakios, Lauren E ^a   Randall, Linnell B ^a   Parnell, Michael J ^b   Zhong, Guangming ^a   Caldwell, Harlan D ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CHLAMYDIA; CONTROLLED STUDY; GENETIC ASSOCIATION; IMMUNE RESPONSE; INFECTION RATE; MACACA; NONHUMAN; PLASMID; PRIMATE; PRIORITY JOURNAL; TRACHOMA;

ANIMALS; CHLAMYDIA TRACHOMATIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACACA FASCICULARIS; MAJOR HISTOCOMPATIBILITY COMPLEX; TRACHOMA; VACCINES, ATTENUATED;

EID: 80055117011     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111266     Document Type: Article

References (27)

1. Bailey, R., T. Duong, R. Carpenter, H. Whittle, and D. Mabey. 1999. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol. Infect. 123:479-486. http://dx.doi.org/10.1017/S0950268899003076.
2. Brunham, R.C., D.J. Zhang, X. Yang, and G.M. McClarty. 2000. The potential for vaccine development against chlamydial infection and disease. J. Infect. Dis. 181:S538-S543. http://dx.doi.org/10.1086/315630
3. Caldwell, H.D., J. Kromhout, and J. Schachter. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176..
4. Carlson, J.H., S.F. Porcella, G. McClarty, and H.D. Caldwell. 2005. Comparative genomic analysis of Chlamydia trachomatis oculotropic and genitotropic strains. Infect. Immun. 73:6407-6418. http://dx.doi.org/10.1128/IAI.73.10.6407-6418.2005.
5. Carlson, J.H., W.M. Whitmire, D.D. Crane, L. Wicke, K. Virtaneva, D.E. Sturdevant, J.J. Kupko III, S.F. Porcella, N. Martinez-Orengo, R.A. Heinzen, et al. 2008. The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor. Infect. Immun. 76:2273-2283. http://dx.doi.org/10.1128/IAI.00102-08
6. Collier, L.H. 1966. The present status of trachoma vaccination studies. Bull. World Health Organ. 34:233-241..
7. Kari, L., W.M. Whitmire, J.H. Carlson, D.D. Crane, N. Reveneau, D.E. Nelson, D.C. Mabey, R.L. Bailey, M.J. Holland, G. McClarty, and H.D. Caldwell. 2008. Pathogenic diversity among Chlamydia trachomatis ocular strains in nonhuman primates is affected by subtle genomic variations. J. Infect. Dis. 197:449-456. http://dx.doi.org/10.1086/525285
8. Kari, L., W.M. Whitmire, D.D. Crane, N. Reveneau, J.H. Carlson, M.M. Goheen, E.M. Peterson, S. Pal, L.M. de la Maza, and H.D. Caldwell.2009. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182:8063-8070. http://dx.doi.org/10.4049/jimmunol.0804375
9. Lakew, T., J. House, K.C. Hong, E. Yi, W. Alemayehu, M. Melese, Z. Zhou, K. Ray, S. Chin, E. Romero, et al. 2009. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl. Trop. Dis. 3:e376. http://dx.doi.org/10.1371/journal.pntd.0000376
10. Matsumoto, A., H. Izutsu, N. Miyashita, and M. Ohuchi. 1998. Plaque formation by and plaque cloning of Chlamydia trachomatis biovar trachoma. J. Clin. Microbiol. 36:3013-3019..
11. Morrison, R.P., and H.D. Caldwell. 2002. Immunity to murine chlamydial genital infection. Infect. Immun. 70:2741-2751. http://dx.doi.org/10.1128/IAI.70.6.2741-2751.2002.
12. O'Connell, C.M., and K.M. Nicks. 2006. A plasmid-cured Chlamydia muridarum strain displays altered plaque morphology and reduced infectivity in cell culture. Microbiology. 152:1601-1607. http://dx.doi.org/10.1099/mic.0.28658-0
13. O'Connell, C.M., R.R. Ingalls, C.W.J. Andrews Jr., A.M. Scurlock, and T. Darville. 2007. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J. Immunol. 179:4027-4034.
14. Palmer, L., and S. Falkow. 1986. A common plasmid of Chlamydia trachomatis. Plasmid. 16:52-62. http://dx.doi.org/10.1016/0147-619X(86)90079-X
15. Rodgers, A.K., J. Wang, Y. Zhang, A. Holden, B. Berryhill, N.M. Budrys, R.S. Schenken, and G. Zhong. 2010. Association of tubal factor infertility with elevated antibodies to Chlamydia trachomatis caseinolytic protease P. Am. J. Obstet. Gynecol. 203:494.e7-494: e14..
16. Schachter, J. 1978. Chlamydial infections (third of three parts). N. Engl. J. Med. 298:540-549. http://dx.doi.org/10.1056/NEJM197803092981005.
17. Schachter, J. 1985. Overview of Chlamydia trachomatis infection and the requirements for a vaccine. Rev. Infect. Dis. 7:713-716. http://dx.doi.org/10.1093/clinids/7.6.713.
18. Sturdevant, G.L., L. Kari, D.J. Gardner, N. Olivares-Zavaleta, L.B. Randall, W.M. Whitmire, J.H. Carlson, M.M. Goheen, E.M. Selleck, C. Martens, and H.D. Caldwell. 2010. Frameshift mutations in a single novel virulence factor alter the in vivo pathogenicity of Chlamydia trachomatis for the female murine genital tract. Infect. Immun. 78:3660-3668. http://dx.doi.org/10.1128/IAI.00386-10
19. Su, H., N.G. Watkins, Y.X. Zhang, and H.D. Caldwell. 1990. Chlamydia trachomatis-host cell interactions: role of the chlamydial major outer membrane protein as an adhesin. Infect. Immun. 58:1017-1025..
20. Su, H., R. Messer, W. Whitmire, S. Hughes, and H.D. Caldwell. 2000. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains. Infect. Immun. 68:192-196. http://dx.doi.org/10.1128/IAI.68.1.192-196.2000
21. Taylor, H.R. 2008. Trachoma is an ancient disease and a weapon of mass destruction. In Trachoma: A Blinding Scourge From the Bronze Age to the Twenty-First Century. Center for Eye Research Australia, East Melbourne VIC, Australia. 1-15..
22. Taylor, H.R., R.A. Prendergast, C.R. Dawson, J. Schachter, and A.M. Silverstein. 1981. An animal model for cicatrizing trachoma. Invest. Ophthalmol. Vis. Sci. 21:422-433..
23. Taylor, H.R., S.L. Johnson, R.A. Prendergast, J. Schachter, C.R. Dawson, and A.M. Silverstein. 1982. An animal model of trachoma II. The importance of repeated reinfection. Invest. Ophthalmol. Vis. Sci. 23:507-515..
24. Vogel, G. 2006. Infectious diseases. Tackling neglected diseases could offer more bang for the buck. Science. 311:592-593. http://dx.doi.org/10.1126/science.311.5761.592a.
25. Wang, J., Y. Zhang, C. Lu, L. Lei, P. Yu, and G. Zhong. 2010. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J. Immunol. 185:1670-1680. http://dx.doi.org/10.4049/jimmunol.1001240
26. West, S.K., B. Munoz, H. Mkocha, C.A. Gaydos, and T.C. Quinn. 2011. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J. Infect. Dis. 204:268-273. http://dx.doi.org/10.1093/infdis/jir257.
27. World Health Organization. 1998. Global elimination of blinding trachoma. Resolution WHA 51.11 adopted by the World Health Assembly 16 May 1998.